Roche convinced new meds can offset biosimilar threats; EU finds no safety issues with Merck, GSK HPV jabs;

@FiercePharma: Australia looks to save cash by cutting scripts for common drugs. FiercePharmaAsia report | Follow @FiercePharma

@EricPFierce: makes sure Denmark gets some of the action as it starts massive build up. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: Allergan pumps up its sales rep tally amid Viberzi launch, aesthetics push. FiercePharmaMarketing story | Follow @CarlyHFierce

> Roche ($RHHBY) is "absolutely convinced" that its new meds will offset biosimilar threats to its older drugs. More

> EU regulators have found no safety concerns linking GlaxoSmithKline's ($GSK) and Merck's ($MRK) HPV shots with two conditions known as complex regional pain syndrome and postural orthostatic tachycardia syndrome. More

> Endo ($ENDP) CEO Rajiv De Silva is working to distance himself and his company from his embattled former employer, Valeant ($VRX). More

Medical Device News

@FierceMedDev: Dx Digest: Illumina launches $250M share repurchase program; Foundation Medicine stumbles with Q3 earnings miss. More | Follow @FierceMedDev

@VarunSaxena2: IYCMI from FierceDrugDelivery: Investigational drug enables faster absorption of bioresorbable drug-eluting stents. Article | Follow @VarunSaxena2

@EmilyWFierce: Medicaid calls on Gilead, AbbVie to answer hep C drug pricing questions. FiercePharma article | Follow @EmilyWFierce

> GAO study finds 510(k)-cleared devices account for 94% of unplanned postmarket safety studies. More

> Theranos scouts out new lab director amid testing fallout. Article

Biotech News

@FierceBiotech: Gilead wins FDA approval for a new HIV combo pill with rivals at its heels. Report | Follow @FierceBiotech

@JohnCFierce: Andy Futreal at MD Anderson is joining my Big Data:2025 panel at . | Follow @JohnCFierce

> AstraZeneca poaches ZS Pharma for $2.7B, beating Actelion to the punch. Report

> Sanofi bets another $1.7B on diabetes to pad its lagging pipeline. Story

> Under Pfizer's gaze, Allergan's Saunders softens his tone on early-stage R&D. Article

And Finally... Injuries from Mylan's ($MYL) Epipen are rare but have the potential to be serious for children. Report